Programme

Opening Ceremony

Welcoming words

Juha-Matti Savola, Chairman of the Finnish Bioindustries, Juvantia Pharma Ltd

Opening Words

Paavo Lipponen, Speaker of the Parliament of Finland
Leena Peltonen-Palotie, University of Helsinki and National Public Health Institute
G. Steven Burrill, Burrill & Company

Plenary session

Chair: Mart Saarma, University of Helsinki

Richard J. Roberts, New England Biolabs

Discovering Research Reagents Using Bioinformatics and Genomics

Session: Novel Methods to Identify Drug Targets

Chair: Risto Renkonen, Medicel Ltd, University of Helsinki

Gitte Neubauer, Cellzome

Novel Proteomics: Enabling De-risked Target Identification

Matej Orešič, VTT Biotechnology

Making sense of knowns and unknowns in modeling of mammalian complexity

Kari Alitalo, University of Helsinki

Mouse Models for Angiogenesis, Lymphangiogenesis and Metastasis

Session: Drug Targets Through Genomics

Chair: Aarno Palotie, University of Helsinki

Leif Groop, Malmö University Hospital

Multidisciplinary Approaches to Identify Critical Targets in Type 2 Diabetes

Tarja Laitinen, GeneOS

Genetic Studies in the Identification of Novel Drug Targets—The Finnish Asthma Study

Reception at the Helsinki City Hall

By the courtesy of the City of Helsinki

Plenary session

Chair: Tarja Laitinen, GeneOs Ltd

David R. Cox, Perlegen Sciences Inc.

Personalized Medicine

Session: From Bench to Bedside

Chair: Tomi Mäkelä, University of Helsinki

Salah-Dine Chibout, Novartis

Application of Expression Profiling Methods for Early Drug Selection

Peter Shaw, Merck & Co Inc

Clinical Applications for Pharmacogenomics

Robert G. Pietrusko, Millenium Pharmaceuticals

The Rapid Development Process for VELCADE®

Ruth March, AstraZeneca Ltd

Examples of the challenges and opportunities of applying pharmacogenetics to the drug development process

Session: Genomic Diagnostics

Chair: Marjut Ranki-Pesonen, Orion Pharma Ltd

Gabriele A. Beer, Roche Molecular Diagnostics

AmpliChip CYP450: Advancing Pharmacogenetic Diagnostics Into Clinical Practice

Olli Kallioniemi, VTT Biotechnology

Integrating in silico, molecular, cellular and clinical profiling for therapeutic target and biomarker discovery